Floatz logo

Trastuzumab Emtansine

HER-2 Positive Breast Cancer

Dana-Farber Cancer Instituteantibody_drug_conjugatePhase 2/3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the HER-2 Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
National Taiwan University Hospital
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
National Taiwan University Hospital
Phase 3BB
Carboplatin
Instituto do Cancer do Estado de São Paulo
Phase 2/3BB
Inno-206
National Taiwan University Hospital
Phase 2BB
Letrozole
Alliance Foundation Trials, LLC.
Phase 3BB

View all 25 →

Same molecule, other indications

Trastuzumab Emtansine is also rated in:

Breast Inflammatory CarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →